Theranostics News and Research

RSS

Immuno-PET detects changes in different cancer receptors in response to targeted therapies

Immuno-positron emission tomography (PET) imaging can provide early insight into a tumor's response to targeted therapy, allowing physicians to select the most effective treatment for patients who have cancer.

13 Mar 2021

An optimized process to isolate and purify magnetic nanoparticles

Magnetic nanoparticles biosynthesized by bacteria might soon play an important role in biomedicine and biotechnology. Researchers of the University of Bayreuth have now developed and optimized a process for the isolation and purification of these particles from bacterial cells.

19 Feb 2021

Molecular imaging can predict response to novel metastatic breast cancer treatment

Molecular imaging can successfully predict response to a novel treatment for ER-positive, HER2-negative metastatic breast cancer patients who are resistant to hormonal therapy.

17 Feb 2021

Metal-containing radiopharmaceuticals could improve access to diagnostic imaging of AD

A team of researchers from the Laboratory of Biophysics at NUST MISIS, Lomonosov Moscow State University and D. Mendeleev University of Chemical Technology of Russia has summarized metal-containing diagnostic agents for positron emission tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT) imaging of Alzheimer's disease (AD).

9 Feb 2021

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine.

8 Feb 2021

Newly designed Biomesh minimizes postsurgical complications of hernia repair

Hernias are one of the most common soft tissue injuries. Hernias form when intra-abdominal content, such as a loop of the intestine, squeezes through weak, defective or injured areas of the abdominal wall.

25 Jan 2021

Study offers data related to physicians' potential liability to use AI in personalized medicine

Physicians who follow artificial intelligence (AI) advice may be considered less liable for medical malpractice than is commonly thought, according to a new study of potential jury candidates in the U.S.

11 Jan 2021

NET study: New theranostic approach effective in reducing tumor volume and extending lifespan

A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival.

16 Dec 2020

68Ga-pentixafor PET imaging is an effective diagnostic tool for CNS B-cell lymphoma

Positron emission tomography (PET) imaging with 68Ga-pentixafor is an effective diagnostic tool for central nervous system (CNS) B-cell lymphoma, according to a proof-of-concept study published in the December issue of The Journal of Nuclear Medicine.

10 Dec 2020

Research shows how targeted microbubbles can carry powerful cancer drugs

New research has shown how microbubbles carrying powerful cancer drugs can be guided to the site of a tumor using antibodies.

8 Dec 2020

Novel ALS study effectively visualizes neuroinflammation

A novel ALS (amyotrophic lateral sclerosis) study has pooled data from multiple sites to effectively visualize neuroinflammation, which is key to developing drugs to treat the disease.

2 Dec 2020

UCLA, UCSF obtain FDA approval for PSMA PET imaging in men with prostate cancer

The University of California's two nationally ranked medical centers, UCSF and UCLA, and their nuclear medicine teams have obtained approval from the U.S. Food and Drug Administration to offer a new imaging technique for prostate cancer that locates cancer lesions in the pelvic area and other parts of the body to which the tumors have migrated.

2 Dec 2020

Novel, highly specific treatment method for hyperinsulinemic hypoglycemia

A new method to treat hyperinsulinemic hypoglycemia has proven highly selective in targeting lesions and effective in slowing tumor growth, according to research published in the November issue of the Journal of Nuclear Medicine.

9 Nov 2020

Novel radioimmunotherapy proven effective in reversing resistance to lymphoma therapy

A new radioimmunotherapy has proven effective in reversing resistance to the most commonly used lymphoma drug, rituximab, according to research published in the October issue of The Journal of Nuclear Medicine.

8 Oct 2020

Cerenkov luminescence imaging can accurately assess surgical margins during radical prostatectomy

A new intraoperative imaging technique, Cerenkov luminescence imaging (CLI), can accurately assess surgical margins during radical prostatectomy, according to a first-in-human research published in the October issue of the Journal of Nuclear Medicine.

7 Oct 2020

PET/MRI reduces radiation exposure, improves lesion detectability in select cancers

A single-center observational study of more than 1,000 oncological examinations has demonstrated that positron emission tomography/magnetic resonance imaging (PET/MRI) facilitates cancer staging as well as PET/computed tomography (PET/CT) and improves lesion detectability in select cancers, potentially helping to promote fast, efficient local and whole-body staging in one step.

17 Sep 2020

Simple process could enhance personalization of cancer therapy

Researchers have developed a simplified process that could enhance personalization of cancer therapy based on a single nuclear medicine scan.

12 Aug 2020

New alpha-radioimmunotherapy for multiple myeloma shows promise in preclinical study

A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of the Journal of Nuclear Medicine. Given the long half-life, central production and worldwide distribution of 212Pb-anti-CD38, researchers have determined that the α-radioimmunotherapy is not only effective but also clinically feasible as a multiple myeloma treatment.

6 Aug 2020

Gene signature explains why 18F-FDG imaging performs better for PSMA-suppressed prostate cancer patients

Scientists have uncovered the genomic signature to explain why 18F-FDG imaging performs better than PSMA-targeted imaging for prostate cancer patients with low or no expression of the prostate-specific membrane antigen (PSMA).

23 Jul 2020

Study shows safety and effectiveness of PET radiotracer in imaging glioblastomas

A first-in-human study presented at the Society of Nuclear Medicine and Molecular Imaging 2020 Annual Meeting has demonstrated the safety, favorable pharmacokinetic and dosimetry profile of 64Cu-EBRGD, a new, relatively long-lived PET tracer, in patients with glioblastomas.

13 Jul 2020